2019-001123-13
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Verastem, Inc.·EU Clinical Trials RegisterNo longer available
Study focus
- Disease/Condition
- Peripheral T-cell Lymphoma
Sponsor & location
- Primary sponsor
- Verastem, Inc.
Timeline & enrollment
- Phase
- N/A
- Start date
- N/A
- End date
- N/A
Primary outcome
1. Primary leukemic PTCL subtypes (i.e., T-cell prolymphocytic leukemia, T-cell large granular lymphocytic leukemia, Adult T-cell leukemia/lymphoma and Aggressive NK-cell leukemia) or transformed mycosis fungoides
ICD-10 classifications
Peripheral T-cell lymphoma, not elsewhere classifiedCutaneous T-cell lymphoma, unspecifiedMature T/NK-cell lymphomasAngioimmunoblastic T-cell lymphomaOther mature T/NK-cell lymphomas
Data source
- Registry
- EU Clinical Trials Register
- Trial ID
- 2019-001123-13
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for 2019-001123-13 through Pure Global AI's free database. This phase not specified trial is sponsored by Verastem, Inc. and is currently No longer available. The study focuses on Peripheral T-cell Lymphoma.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.